glp-1 receptor agonists are contraindicated in transforming diabetes care by improving blood sugar control, supporting weight loss, and reducing cardiovascular risk when used appropriately. Evidence-based therapy selection, correct dosing, and patient counseling are Exploring the Side Effects of
Description
Another noteworthy point: the medicines seem to work for a variety of people
(2023) Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
Roughly 1 in 8 (12%) consumers have taken a GLP-1 drug , per KFF, and that share is likely to rise: 26% of US consumers plan to take a weight loss drug to achieve their 2025 New Year's resolution goals , per Tebra
Thats a significantly higher percentage than most other non-surgical weight loss treatments
Protein helps keep you feeling full longer, which is beneficial for those using GLP-1 medications for weight management
A 3-month open-label trial investigated the weight loss and glycemic control effects of benaglutide in patients with T2DM
